A combination of two immunotherapy drugs delivered an “encouraging” response rate in patients with advanced solid tumors, offering new hope for improvement in mesothelioma treatments. The clinical trial revealed a 37.7% objective response to treatment with anti-CTLA-4 human immunoglobulin (Ig) G1 monoclonal antibody CS1002 and the anti-PD-1 humanized recombinant IgG4 monoclonal antibody CS1003, also known
Dr. Corey J. Langer is a medical oncologist and Director of Thoracic Oncology at the Hospital of the University of Pennsylvania and Abramson Cancer Center in Philadelphia, Pennsylvania. He specializes in the treatment of patients diagnosed with lung cancers and malignant pleural mesothelioma and is particularly effective in the use of targeted treatment protocols that
Dr. David Harpole is a thoracic surgeon whose areas of expertise include mesothelioma surgery, thoracic oncologic surgery, lung cancer surgery, surgery for congenital and acquired chest wall abnormalities, and esophageal cancer surgery at the Duke Cancer Institute in Durham, North Carolina. He specializes in minimally invasive thoracic surgery. Dr. Harpole has been in practice for
Dr. Luis J. Herrera specializes in the surgical treatment of tumors of the chest, including malignant pleural mesothelioma, lung cancer, and cancers of the esophagus, mediastinum, and chest wall. He practices at Orlando Health Cancer Institute, where he is the medical director of the Rod Taylor Thoracic Care Center. Dr. Herrera has expertise in a
Dr. Amin Mirhadi is a radiation oncologist at Cedars Sinai Medical Center and the Cedars-Sinai Samuel Oschin Comprehensive Cancer Center in Los Angeles, California. He is part of the multidisciplinary mesothelioma and lung cancer team and also provides his expertise in radiation therapy to the treatment of general pulmonology patients, colon cancer patients, and breast
Dr. Sally York is a medical oncologist and research scientist whose primary clinical focus is on treating patients with lung cancer, thymic cancers, mesothelioma, and other thoracic malignancies. She practices at Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Institute, where she is an Assistant Professor of Medicine. She is also the Associate Director for Clinical
Dr. Joel Neal is a thoracic oncologist who treats patients with lung cancer, malignant pleural mesothelioma, and other thoracic malignancies at the Stanford Cancer Institute in Palo Alto, California. His treatment relies on the findings of his clinical trials, which focus on overcoming acquired resistance to targeted therapies, understanding and improving the efficacy of immunotherapy
Dr. Horn is the Global Clinical Head for Lung Cancer and Lung Cancer Strategy for AstraZeneca, working within the company to progress research and delivery of better cures for patients diagnosed with lung cancer. Speaking of her work, she says, “Recent research has helped us better understand lung cancer biology and our approach to targeted
Dr. Fadi S. Braiteh is a medical oncologist at Comprehensive Cancer Centers of Nevada. Board-certified in Medical Oncology, Internal Medicine, and Palliative Medicine, he specializes in the treatment of gastrointestinal and digestive system cancers, breast cancer, and thoracic malignancies including lung cancer and malignant pleural mesothelioma. Dr. Braiteh’s approach to patient care is that he
Dr. Anita Lyn Sabichi is a medical oncologist who treats lung cancer and malignant pleural mesothelioma patients, as well as those with genitourinary cancers and head and neck cancers, at the Baylor College of Medicine, the Dan L. Duncan Comprehensive Cancer Center, and the Michael E. DeBakey VA Medical Center in Houston, Texas. She works